Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HCL versus PROCHLORPERAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HCL versus PROCHLORPERAZINE.
FLUPHENAZINE HCL vs PROCHLORPERAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine is a phenothiazine antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic system. It also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminergic effects.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
Oral: 2.5-10 mg/day in divided doses every 6-8 hours; maintenance: 1-5 mg/day. IM: 1.25-2.5 mg every 6-8 hours. Decanoate (long-acting): 12.5-25 mg IM every 2-4 weeks.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life is 15-30 hours (mean 24 hours) after IM administration; up to 9-12 hours after oral dosing due to first-pass metabolism. Steady-state reached in 5-10 days.
Terminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
Primarily hepatic metabolism via CYP2D6; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~20-30% of metabolites. Renal clearance is negligible.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."